TI-002
/ Trigemina
- LARVOL DELTA
Home
Next
Prev
1 to 10
Of
10
Go to page
1
June 30, 2020
TACTI-002: Combination Study With Soluble LAG-3 Fusion Protein Eftilagimod Alpha (IMP321) and Pembrolizumab in Patients With Previously Untreated Unresectable or Metastatic NSCLC, or Recurrent PD-X Refractory NSCLC or With Recurrent or Metastatic HNSCC
(clinicaltrials.gov)
- P2; N=109; Recruiting; Sponsor: Immutep S.A.; Trial completion date: Jun 2021 ➔ Dec 2021; Trial primary completion date: Jun 2020 ➔ Dec 2020
Clinical • Combination therapy • Trial completion date • Trial primary completion date • Head and Neck Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma of Head and Neck • Thoracic Cancer • PD-L1
July 01, 2020
"#Immutep Completes Recruitment For Part A Of Phase II #Tacti002 Study $IMMP https://t.co/qdbTjORd7y"
(@1stOncology)
October 03, 2018
"$IMMP IMP321 (The only APC targeting LAG-3 product currently in clinical development) at #SITC2018 : TACTI-mel and TACTI-002 update"
(@CaesarBiotech)
Clinical • Oncology
February 22, 2020
"#Immutep Reports Positive #TACTI002 Data https://t.co/O1cCy8QTyN"
(@1stOncology)
February 05, 2020
"#Immutep to Present #TACTI002 Interim Data at German Cancer Congress $IMMP https://t.co/Jx02R2a9Dj"
(@1stOncology)
January 10, 2020
"#Immutep Expands Part C Of #Tacti002 Due To Positive Data $IMMP https://t.co/PPfVYDMUI0"
(@1stOncology)
July 09, 2019
Immutep Raises A$10 Million Via Private Placement and Underwritten Entitlement Offer
(GlobeNewswire, Immutep Limited)
- The Company will use the proceeds received from the Private Placement and the Entitlement Offer to finance its LAG-3 related clinical program in immuno-oncology and autoimmune disease. This includes the ongoing clinical development of eftilagimod alpha (“efti” or “IMP321”), via its TACTI-mel, TACTI-002, and INSIGHT clinical studies, development of IMP761 and for general corporate.
Financing
June 03, 2019
Immutep Presentation at ASCO 2019
(GlobeNewswire, Immutep Limited)
- "The two posters related to Immutep’s lead product candidate eftilagimod alpha (“efti” or “IMP321”). The first poster (TPS2667 - #299b) provided an overview of the ongoing Phase II TACTI-002 (Two ACTive Immunotherapies) clinical trial...This multicenter Phase II clinical trial is evaluating the combination of efti with MSD’s KEYTRUDA® (or pembrolizumab, an anti-PD-1 therapy) in up to 109 patients with second line head and neck squamous cell carcinoma or non-small cell lung cancer in first and second line...The second poster related to efti (TPS2651 - #291b) provided an overview of the two additional INSIGHT clinical trial stratas of the prospective investigator-initiated phase I study."
Clinical
March 01, 2019
TACTI-002: Combination Study With Soluble LAG-3 Fusion Protein Eftilagimod Alpha (IMP321) and Pembrolizumab in Patients With Previously Untreated Unresectable or Metastatic NSCLC, or Recurrent PD-X Refractory NSCLC or With Recurrent or Metastatic HNSCC
(clinicaltrials.gov)
- P2; N=109; Recruiting; Sponsor: Immutep S.A.; Not yet recruiting ➔ Recruiting
Clinical • Combination therapy • Enrollment open
January 11, 2019
TACTI-002: Combination Study With Soluble LAG-3 Fusion Protein Eftilagimod Alpha (IMP321) and Pembrolizumab in Patients With Previously Untreated Unresectable or Metastatic NSCLC, or Recurrent PD-X Refractory NSCLC or With Recurrent or Metastatic HNSCC
(clinicaltrials.gov)
- P2; N=110; Not yet recruiting; Sponsor: Immutep S.A.; Initiation date: Nov 2018 ➔ Feb 2019
Clinical • Combination therapy • Trial initiation date
1 to 10
Of
10
Go to page
1